Cigna vs Labcorp
Cigna reported revenue of $274.9 billion in fiscal 2025, 19.7 times Labcorp's $14.0 billion in fiscal 2025. Cigna's revenue grew 11.2% in its latest year, and Labcorp's grew 7.2%. Cigna had an operating margin of 3.4%, against 9.9% at Labcorp.
Side by side
| Cigna | Labcorp | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $274.9B | $14.0B |
| Revenue growth | 11.2% | 7.2% |
| Revenue growth a year, last 5 years | 11.4% | −0.0% |
| Gross margin | — | 28.8% |
| Operating margin | 3.4% | 9.9% |
| Net margin | 2.2% | 6.3% |
| Free cash flow | — | $1.2B |
| Free cash flow margin | — | 8.6% |
| Return on capital | 11.7% | 8.2% |
| Net debt to EBITDA | 1.9x | 2.5x |
| Dividends and buybacks | $5.2B | $691M |
| Change in diluted share count | −5.2% | −0.7% |
| Last close | $305.78 | $329.90 |
| P/E at the last close | 12.6× | 27.3× |
| Insider trades, last 12 months | bought $999,932, sold $66.8 million | sold $13.7 million |
| Piotroski F-score | 7 of 8 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CignaLabcorp
Operating margin
Percent of revenue
CignaLabcorp
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CignaLabcorp